Agios Pharmaceuticals Newsroom

Agios' Supplemental New Drug Application for Its Thalassemia Treatment Gets FDA Nod

Seeking AlphaJan 8 08:30 ET

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BusinesswireJan 8 08:00 ET

Agios Pharmaceuticals Says FDA Accepted SNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia

BenzingaJan 8 07:04 ET

Express News | Agios Pharmaceuticals Inc - Pdufa Goal Date for Pyrukynd Snda Is September 7, 2025

ReutersJan 8 07:00 ET

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (Mitapivat) in Adult Patients With Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

GlobeNewswireJan 8 07:00 ET

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55

Moomoo NewsJan 7 07:36 ET · Ratings

Agios Pharmaceuticals Price Target Lowered to $55 From $60 at BofA

TipRanksJan 7 07:22 ET

Express News | Agios Pharmaceuticals - to Discontinue Pyrukynd if Hepatic Injury Due to Pyrukynd Is Suspected

ReutersJan 6 06:40 ET

Express News | Agios Pharmaceuticals - Uspi Sections Updated to Include Liver Injury Information

ReutersJan 6 06:38 ET

Express News | Agios Pharmaceuticals - FDA Approves Update to Uspi for Pyrukynd for Hemolytic Anemia

ReutersJan 6 06:38 ET

How to Navigate the Stock and Bond Markets in 2025 -- Journal Report

Dow JonesJan 3 10:00 ET

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewswireJan 3 07:00 ET

The Best U.S. Value Stocks by Quant: AGIO, DLX, PPC

Seeking AlphaDec 26, 2024 11:22 ET

TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating

Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Express News | Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight

BenzingaDec 18, 2024 08:57 ET

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

BenzingaDec 18, 2024 07:03 ET

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

GlobeNewswireDec 18, 2024 07:00 ET

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

BenzingaDec 16, 2024 12:33 ET

Here's Why Agios Stock Plummeted More Than 20% on Monday

Zacks Dec 10, 2024 10:00 ET

Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75

Moomoo NewsDec 10, 2024 08:31 ET · Ratings